Spark Therapeutics, Inc. (ONCE) saw its loss widen to $52.29 million, or $1.70 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $25.58 million, or $0.95 a share.
Revenue during the quarter went down marginally by 1.10 percent to $1.27 million from $1.29 million in the previous year period.
Operating loss for the quarter was $52.87 million, compared with an operating loss of $25.84 million in the previous year period.
"I'm pleased to announce that our work on the rolling BLA for voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease is now complete. The application formally will be submitted to the FDA next week," said Jeffrey D. Marrazzo, chief executive officer. "We are excited to reach this major milestone, and will now shift our immediate regulatory focus to completing the Marketing Authorization Application submission for Europe by the end of July. Today, we report interim results of our second investigational gene therapy for a retinal disease, SPK-7001 in choroideremia, and that we plan to provide an initial update on the Phase 1/2 trial for SPK-8011 in hemophilia A in July or August 2017."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
